These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25613565)

  • 1. Autologous Hematopoietic Stem Cells transplantation and genetic modification of CCR5 m303/m303 mutant patient for HIV/AIDS.
    Esmaeilzadeh A; Farshbaf A; Erfanmanesh M
    Med Hypotheses; 2015 Mar; 84(3):216-8. PubMed ID: 25613565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
    Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
    Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
    Allers K; Schneider T
    Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
    Gupta RK; Abdul-Jawad S; McCoy LE; Mok HP; Peppa D; Salgado M; Martinez-Picado J; Nijhuis M; Wensing AMJ; Lee H; Grant P; Nastouli E; Lambert J; Pace M; Salasc F; Monit C; Innes AJ; Muir L; Waters L; Frater J; Lever AML; Edwards SG; Gabriel IH; Olavarria E
    Nature; 2019 Apr; 568(7751):244-248. PubMed ID: 30836379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editing CCR5: a novel approach to HIV gene therapy.
    Cornu TI; Mussolino C; Bloom K; Cathomen T
    Adv Exp Med Biol; 2015; 848():117-30. PubMed ID: 25757618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5 as a natural and modulated target for inhibition of HIV.
    Burke BP; Boyd MP; Impey H; Breton LR; Bartlett JS; Symonds GP; Hütter G
    Viruses; 2013 Dec; 6(1):54-68. PubMed ID: 24381033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene.
    Quillent C; Oberlin E; Braun J; Rousset D; Gonzalez-Canali G; Métais P; Montagnier L; Virelizier JL; Arenzana-Seisdedos F; Beretta A
    Lancet; 1998 Jan; 351(9095):14-8. PubMed ID: 9433423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers.
    Solloch UV; Lang K; Lange V; Böhme I; Schmidt AH; Sauter J
    Hum Immunol; 2017 Nov; 78(11-12):710-717. PubMed ID: 28987960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in CCR5 regulation for HIV cure.
    Garg K; Khan AR; Taneja P
    Adv Protein Chem Struct Biol; 2021; 126():123-149. PubMed ID: 34090613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
    Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases.
    Li L; Krymskaya L; Wang J; Henley J; Rao A; Cao LF; Tran CA; Torres-Coronado M; Gardner A; Gonzalez N; Kim K; Liu PQ; Hofer U; Lopez E; Gregory PD; Liu Q; Holmes MC; Cannon PM; Zaia JA; DiGiusto DL
    Mol Ther; 2013 Jun; 21(6):1259-69. PubMed ID: 23587921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.
    Mulherin SA; O'Brien TR; Ioannidis JP; Goedert JJ; Buchbinder SP; Coutinho RA; Jamieson BD; Meyer L; Michael NL; Pantaleo G; Rizzardi GP; Schuitemaker H; Sheppard HW; Theodorou ID; Vlahov D; Rosenberg PS;
    AIDS; 2003 Feb; 17(3):377-87. PubMed ID: 12556692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects.
    Lai Y
    Curr Stem Cell Res Ther; 2012 Jul; 7(4):310-7. PubMed ID: 22486585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
    Pippi F
    Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection.
    Li H; Liu TJ; Hong ZH
    Infect Genet Evol; 2014 Jun; 24():99-104. PubMed ID: 24650919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32.
    Ballana E; Riveira-Munoz E; Pou C; Bach V; Parera M; Noguera M; Santos JR; Badia R; Casadellà M; Clotet B; Paredes R; Martínez MA; Brander C; Esté JA
    Immunobiology; 2013 Apr; 218(4):543-7. PubMed ID: 22818666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential mechanisms for cell-based gene therapy to treat HIV/AIDS.
    Herrera-Carrillo E; Berkhout B
    Expert Opin Ther Targets; 2015 Feb; 19(2):245-63. PubMed ID: 25388088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation.
    Prator CA; Donatelli J; Henrich TJ
    Curr HIV/AIDS Rep; 2020 Aug; 17(4):385-393. PubMed ID: 32519184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
    Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
    Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.